Literature DB >> 434645

Relation of Mycoplasma pneumoniae seroreactivity, immunosuppression, and chronic disease to Legionnaires' disease. A twelve-month prospective study of sporadic cases in Massachusetts.

G F Grady, R F Gilfillan.   

Abstract

From April 1977 through March 1978, 28 presumptive cases of Legionnaires' disease were identified among 432 consecutive candidates having paired sera or tissue samples submitted to the Massachusetts Public Health Laboratories. Among the subgroup of 209 candidates with documented diffuse pneumonia and temperature of 39 degrees C or above, 24 (11.5%) had Legionnaires' disease whereas the diagnostic yield was only four of 223 (1.8%) among the remainder. The case-fatality rate was two of 28 (7%). Patients with Legionnaires' disease when compared to the entire group of candidates were similar in mean age (49 versus 48 years) and frequency of immunosuppressant therapy (15% versus 12%) but were more often male (64% versus 47%) with underlying chronic illness (46% versus 22%). Complement fixation tests against Mycoplasma pneumoniae (whole organisms) showed seroreactivity in 81% of Legionnaires' disease (LD) cases (22 to 27) compared to 13% of non-LD cases; conversely, 29% of all cases seropositive for M. pneumoniae (22 of 75) were seropositive for the LD bacterium compared to only 1% (five of 357) of the remainder. The coincidence of seroreactivity for M. pneumoniae and the LD bacterium is unexplained but suggests that M. pneumoniae seropositive cases should be evaluated for the possibility of Legionnaires' disease.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 434645     DOI: 10.7326/0003-4819-90-4-607

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  17 in total

1.  Post-infectious encephalomyelitis associated with Mycoplasma pneumoniae and Legionella pneumophila infection.

Authors:  P J Easterbrook; E G Smyth
Journal:  Postgrad Med J       Date:  1992-02       Impact factor: 2.401

2.  Measure of immunoglobulin G-, M-, and A-specific titers against Legionella pneumophila and inhibition of titers against nonspecific, gram-negative bacterial antigens in the indirect immunofluorescence test for legionellosis.

Authors:  H W Wilkinson; C E Farshy; B J Fikes; D D Cruce; L P Yealy
Journal:  J Clin Microbiol       Date:  1979-11       Impact factor: 5.948

3.  Laboratory diagnosis of Mycoplasma pneumoniae infection. 1. Direct detection of antigen in respiratory exudates by enzyme immunoassay.

Authors:  T W Kok; G Varkanis; B P Marmion; J Martin; A Esterman
Journal:  Epidemiol Infect       Date:  1988-12       Impact factor: 2.451

4.  Prevalance of antibodies to 15 antigens of Legionellaceae in patients with community-acquired pneumonia.

Authors:  M McIntyre; J B Kurtz; J B Selkon
Journal:  Epidemiol Infect       Date:  1990-02       Impact factor: 2.451

5.  Counterimmunoelectrophoresis in the serodiagnosis of Legionnaires' disease.

Authors:  M Holliday
Journal:  J Clin Pathol       Date:  1983-04       Impact factor: 3.411

6.  Seroreactivity to Mycoplasma pneumoniae and Legionella pneumophila: lack of a statistically significant relationship.

Authors:  E D Renner; C M Helms; N H Hall; W Johnson; Y W Wong; G L Lattimer
Journal:  J Clin Microbiol       Date:  1981-06       Impact factor: 5.948

7.  A rapid microagglutination test for the diagnosis of Legionella pneumophila (serogroup 1) infection.

Authors:  T G Harrison; A G Taylor
Journal:  J Clin Pathol       Date:  1982-09       Impact factor: 3.411

8.  Studies of the specificity of Legionella serology.

Authors:  B B Wentworth; H E Stiefel
Journal:  J Clin Microbiol       Date:  1982-05       Impact factor: 5.948

Review 9.  Legionellosis.

Authors:  J A Blackmon; F W Chandler; W B Cherry; A C England; J C Feeley; M D Hicklin; R M McKinney; H W Wilkinson
Journal:  Am J Pathol       Date:  1981-06       Impact factor: 4.307

Review 10.  Legionella and Legionnaires' disease: 25 years of investigation.

Authors:  Barry S Fields; Robert F Benson; Richard E Besser
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.